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ABSTRACT
Glutaminase, which converts glutamine to glutamate, is involved in Warburg 
effect in cancer cells. Two human glutaminase genes have been identified, GLS 
(GLS1) and GLS2. Two alternative transcripts arise from each glutaminase gene: 
first, the kidney isoform (KGA) and glutaminase C (GAC) for GLS; and, second, the 
liver isoform (LGA) and glutaminase B (GAB) for GLS2. While GLS1 is considered as 
a cancer therapeutic target, the potential role of GLS2 in cancer remains unclear. 
Here, we discovered a series of alkyl benzoquinones that preferentially inhibit 
glutaminase B isoform (GAB, GLS2) rather than the kidney isoform of glutaminase 
(KGA, GLS1). We identified amino acid residues in an allosteric binding pocket 
responsible for the selectivity. Treatment with the alkyl benzoquinones decreased 
intracellular glutaminase activity and glutamate levels. GLS2 inhibition by either alkyl 
benzoquinones or GLS2 siRNA reduced carcinoma cell proliferation and anchorage-
independent colony formation, and induced autophagy via AMPK mediated mTORC1 
inhibition. Our findings demonstrate amino acid sequences for selective inhibition of 
glutaminase isozymes and validate GLS2 as a potential anti-cancer target.
INTRODUCTION
Cancer cells tend to exhibit the Warburg effect, in 
which cellular metabolisms proceed via: 1) an altered 
glucose metabolism characterized by a high rate of 
glycolysis followed by lactic acid fermentation; and 2) 
up-regulated glutaminolysis by increasing glutaminase 
activity. Glutamine is essential for cancer cell proliferation, 
especially in the context of tricarboxylic acid (TCA) cycle 
anaplerosis. Glutaminase plays an essential role converting 
glutamine to glutamate, which is converted by glutamate 
dehydrogenase into α-ketoglutarate. This α-ketoglutarate 
enters the TCA cycle where it is involved in the production 
of ATP, nucleotides, certain amino acids, lipids, and 
glutathione in mitochondria [1]. Recently, glutaminase 
has emerged as a drug target for the development of 
glutaminase inhibitors for the treatment of cancerous 
disease [2]. However, only a few series of glutaminase 
inhibitors for GLS1 have been identified, and only partial 
in vivo anti-cancer efficacy has been demonstrated [3-6]. 
There are two human glutaminase genes, GLS 
(GLS1) and GLS2, located in chromosomes 2 and 12 
respectively. Two alternative transcripts arise from 
each glutaminase gene: the kidney isoform (KGA) and Oncotarget 6088 www.impactjournals.com/oncotarget
glutaminase C (GAC) for GLS1; and the liver isoform 
(LGA) and glutaminase B (GAB) for GLS2 [7]. 
The dimer-to-tetramer transition is essential for 
the enzymatic activation of glutaminase, which is active 
as a tetramer. Phosphate enhances this activation by 
facilitating the dimer-to-tetramer transition and substrate 
entry to the binding pocket by competing with the product 
glutamate [3, 8]. Each glutaminase isoform has distinct 
kinetic and molecular characteristics, and the activity of 
each is also modulated by a variety of compounds, such as 
glutamate, citrate, calcium, certain long chain fatty acids, 
fatty acyl-CoA derivatives, TCA cycle intermediates, and 
protons [9], all of which are present under physiological 
conditions. Therefore, the kinetic and allosteric properties 
of the enzyme and the physiological environment are 
essential for regulating the enzyme activity in situ. Also, 
the differentiated amino acid residues or domains of the 
glutaminase isozymes provide potential binding pockets 
for selective allosteric modulators. For example, BPTES 
(bis-2-(5-phenylacetimido-1,2,4-thiadiazol-2-yl) ethyl 
sulfide), a GLS1 selective inhibitor, binds GAC through 
a differentiated gating loop close to the glutamine 
substrate binding site and locks the GAC tetramer into a 
nonproductive conformation [3].
In contrast to the disease indications of the KGA and 
GAC (GLS1) inhibitors described for anti-cancer [5, 6, 
10], the biological role of GLS2 is still under exploration. 
GLS2 was found to regulate energy metabolism and 
antioxidant function as a tumor suppressor gene [11-
13]when  ectopically  overexpressed  [11];  enrichment 
with LGA inhibits glioma cell growth and facilitates 
chemotherapeutic  intervention  [14].  However,  knock-
down of GLS2 expression sensitizes cervical cancer to 
ionizing radiation and thus reduces tumor size through 
decreasing cellular glutathione and NADH [15]. 
Therefore, more work is needed to clarify and demonstrate 
the role of GLS2 in cancer cell growth.
Glutaminase  inhibition  blocks  the  conversion  of 
glutamine to glutamate and thus disables the conversion 
of  glutamate  into  α-ketoglutarate  by  glutamate 
dehydrogenase, which normally enters the TCA cycle to 
provide energy and bio-precursors for cancer cell growth. 
Autophagy is a catabolic process generally activated 
by such conditions of nutrient deprivation, and results 
in  the  autophagosomic-lysosomal  degradation  of  bulk 
cytoplasmic contents. Autophagy is initiated and promoted 
by AMPK_ULK1 axis but inhibited by mTORC1 [16]. 
AMPK senses energy changes in cells and is activated 
when nutrients are depleted [17]. Rapamycin inhibits the 
Warburg effect [18, 19] and glutaminolysis feeds mTORC1 
[20] so that a complex feedback exists between mTOR 
and glutaminase and Warburg effect. mTORC1 is also a 
critical regulator of autophagy induction and activation of 
mTORC1 suppresses autophagy. AMPK interacts with, 
phosphorylates,  and  activates  ULK1  protein  kinase,  a 
key initiator of the autophagic process. Residue Ser317 
of ULK1 is the main phosphorylation site for activation 
by AMPK [16]. In mammals, AMPK regulates autophagy, 
also  involving  inactivation  of  the  mTORC1  pathway 
upon nutrient deficiency through two distinct pathways: 
phosphorylation for activation of Tuberin exchange factor 
or Raptor [21]. Conversely, mTOR phosphorylates ULK1 
at Ser757 and disrupts the interaction between ULK1 and 
AMPK to inhibit autophagy [16]. In addition, the Beclin1 
network also can induce and regulate autophagy via the 
formation of Beclin1-Vps34-Vps15 core complexes, and 
phagophore nucleation. The interaction of BCL2 with 
Beclin1 reduces autophagy. Phosphorylation of BCL2 
by c-Jun N-terminal kinase 1 (JNK1) liberates Beclin1, 
allowing it to enter the nucleation process for autophagy 
[22]. Phosphorylation of Beclin1 by ULK1 at Ser15 (Ser14 
in mice) is also required for full autophagic induction in 
mammals [23].
Natural products are a major source of inspiration 
in drug discovery [24, 25], and constitute a good resource 
for  those  seeking  novel  glutaminase  inhibitors. While 
GLS1 is emerging as a therapeutic target for anticancer 
drugs [5, 6, 10], the biological role of GLS2 is still under 
exploration. Herein, we disclose a series of natural alkyl 
benzoquinones with a glutaminase inhibitory effect. 
Through homologous modeling and mutagenesis, the 
alkyl  benzoquinone  binding  site  was  simulated  and 
demonstrated  to  be  an  allosteric  pocket.  From  the 
allosteric pocket, two divergently differentiated residues 
were found to account for the selective inhibition for GAB 
(an isoform of GLS2) over KGA (an isoform of GLS1). 
Furthermore, inhibition of glutaminase activity by the 
active alkyl benzoquinone AV-1 in carcinoma cells led 
to autophagy via AMPK-mediated ULK1 activation and 
mTORC1 inhibition, ultimately leading to inhibition of 
cancer cell growth.
RESULTS
Purification  of  the  recombinant  human  KGA 
and GAB for screening glutaminase inhibitors 
and analysis of structure-activity relations and 
inhibition modes
A collection of ~200 natural products isolated from 
a variety of indigenous Taiwanese plants were submitted 
for screening against KGA. Human recombinant KGA 
and GAB (Figure 1A) from E. coli were cloned, expressed 
and purified. Characterization of its enzymatic properties 
showed that the recombinant GAB but not KGA responded 
to its substrate glutamine in allosteric and positive 
cooperative manners (Figure 1B and 1C), as previously 
reported for these enzymes purified from human biopsies 
[26]. We first screened the compound collection described 
above for inhibitory activity against the recombinant Oncotarget 6089 www.impactjournals.com/oncotarget
Table 1: Natural alkyl benzoquinones inhibit the enzymatic activities of human KGA and GAB. See Materials and 
Methods for the measurement of the IC50 values. Shown structures are alkyl benzoquinones and alkyl phenols isolated from 
plants Ardisia virens (AV series) and A. kusukuensis (AK series)[27, 28]
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AV-7:  R1=H, R2=OH, n=9
OH
R3
R4
R1
n 1 2
34 5
6
1'
2'
3' AV-8:   R1=OCOCH3, R2=H, R3=OH, R4=OCH3, n=9
AV-9:   R1=R3=OCOCH3, R2=H, R4=OCH3,  n=9
AV-10: R1=OCOCH3, R2=CHO,  R3=OH, R4=OCH3, n=9
AV-11: R1=R3=OCOCH3, R2=H, R4=OCH3, n=11
R2
OH
H3CO
R
n 1 2
34 5
6
1'
2'
3'
AV-12:  R=OH, n=11
AV-13:  R=H, n=3
OH
H3CO
O
11 1 2
34 5
6
1'
2'
3'
OCOCH3
AV-14
OH
R
n
1 2
34 5
6
1'
2'
HO 4
OH
R1
n
1 2
34 5
6
1''
2''
R2 4
OH
R3
R4
OH
1 2
34 5
6
1''
2''
H3CO 10
OH
OH
3'
1'
5'
13''
14''
5' 3'
1'
AK-1: R=H, n=6
AK-2: R=H, n=4
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AK-5: R1=CH3, R2=OH, R3=H, R4=OCH3, n=4
AK-6: R1=CH3, R2=OH, R3=H, R4=OCH3, n=2
AK-7: R1=R3=CH3, R2=R4=OH, n=4
AK-8: R1=R3=CH3, R2=R4=OH, n=2
AK-9: R1=CH3, R2=R4=OH, R3=H, n=4
AK-10: R1=CH3, R2=R4=OH, R3=H, n=2
AK-11: R1=R3=H, R2=OCH3, R4=OH, n=4
AK-12: R1=R3=H, R2=OCH3, R4=OH, n=2
AK-13
AV series AK series
KGA GAB
 Compound ID  IC50 (µM) IC50 (µM)
AV-1  2.1 ± 0.1 0.28 ± 0.02
AV-2  3.9 ± 0.4 0.29 ± 0.05
AV-3  >50 25.1 ± 4.5
AV-4  >50 >50
AV-5  >50 32.5 ± 2.7
AV-6  >50 >50
AV-7  >50 >50
AV-8  2.9 ± 0.1 0.26 ± 0.05
AV-9  >50 31.7 ± 6.7
AV-10  >50 23.1 ± 4.9
AV-11  69.0 ± 3.1 5.7 ± 1.1
AV-12  52.4 ± 15.5 7.6 ± 2.0
AV-13  52.7 ± 2.7 >50
AV-14  41.0 ± 5.2 4.7 ± 1.3
AK-1  73.0 ± 3.0 2.9 ± 0.6
AK-2  76.5 ± 0.9 2.8 ± 0.3
AK-3  76.9 ± 0.8 2.7 ± 10.4
AK-4  59.8 ± 4.6 >50
AK-5  70.0 ± 1.6 2.3 ± 0.4
AK-6  36.7 ± 3.2 2.5 ± 0.3
AK-7  17.5 ± 2.6 2.9 ± 0.8
AK-8  13.9 ± 1.5 3.1 ± 0.5
AK-9  11.9 ± 1.2 2.3 ± 0.5
AK-10  11.7 ± 1.3 2.1±0.1
AK-11  13.4 ± 2.2 2.9±0.5
AK-12  9.6 ± 1.2 2.9 ± 0.6
AK-13  14.4 ± 2.3 2.8 ± 0.4
DON 59.9 ± 8.8 ND*
BPTES 0.08 ± 0.01 63.6 ±3.8
*ND: not determined
GlutaminaseOncotarget 6090 www.impactjournals.com/oncotarget
Figure 1: Kinetic studies on the inhibition of alkyl benzoquinones in glutaminases. (A) Escherichia coli BL21(DE3)pLysS 
harboring pET28a(+)-KGA or pET28a(+)-GAB was propagated in Luria-Bertani broth medium in the presence of kanamycin, from which 
KGA or GAB protein expression was induced by 0.5 mM IPTG. The resultant cell lysate was sonicated and centrifugated for fractions 
of cell pellet (lane 1) and supernatant (lane 2). The supernatant was passed through an affinity column (HisTrapTM HP) and the flow-
through was shown in lane 3, as well as the washes with 100 mM and 150 mM of imidazole for KGA(left panel) or 50 mM of imidazole 
for GAB(right panel) were shown in lane 4. Lane 5 shown was the eluent with 500 mM of imidazole for KGA(left panel) or 200 mM of 
imidazole for GAB(right panel). Molecular markers were indicated as kDa. (B) Inhibition mode of active alkyl benzoquinone AV-1 for 
KGA in the absence of phosphate. (C) Inhibition mode of active alkyl benzoquinone AV-1 for GAB in the absence of phosphate. The 
Cheng-Prusoff equation, Ki=IC50/(1+[S]/Km), was used to calculate Ki values of AV-1 for KGA=1.20±0.06µM and GAB=0.14±0.01µM. 
(D) Dose dependent inhibition of alkyl benzoquinones against the purified recombinant KGA and GAB in the absence of phosphate.Oncotarget 6091 www.impactjournals.com/oncotarget
KGA, and then determined the IC50 values against KGA 
and GAB for the potent compounds (Table 1, Figure 1D). 
Among the active hit compounds, a series of alkyl 
benzoquinones from Ardisia. virens (Table 1, AV series) 
were found to exhibit inhibition of human KGA and GAB 
(Table 1 & Figure 1D). The keto (hydroxyl) groups at 
positions 1 and 4 on the benzoquinone core and the acetate 
group at position 2’ were all found to be essential for 
potency for either KGA or GAB inhibition, by comparing 
the most potent compounds AV-1, AV-2, and AV-8 (KGA, 
IC50 values 2.1±0.1 µM; 3.9±0.4 µM; 2.9±0.1 µM; GAB, 
IC50 values 0.28±0.02 µM; 0.29±0.05µM; 0.26±0.05 µM 
respectively)  to  the  other AV  compounds  (KGA,  IC50 
values > 40 µM; GAB, IC50 values > 4.7 µM) (Table 1).
As the AV compounds were also found to be 
selective for GAB over KGA, the inhibition mode of AV-1 
(the most active) was investigated. AV-1 inhibited both 
KGA and GAB in a mixed non-competitive inhibition; 
when AV-1 concentration was increased from 0 to 30 µM, 
the Km values increased by 2.9- and 1.6-fold and the Vmax 
values decreased to 61% and 54% for KGA and GAB 
respectively (Figure 1 B & 1C). AV-1 exhibited Ki values 
of 1.20±0.06 µM for KGA and 0.14±0.01 µM for GAB, 
as calculated using the Cheng-Prusoff equation; the AV-1 
exerted a positive cooperative manner with the substrate 
glutamine in inhibiting GAB with a Hill coefficient of 
~1.3-1.4 and an independent manner in inhibiting KGA 
with a Hill coefficient of ~1.0-1.2 (Figure 1B & 1C). In 
conclusion, the mechanisms by which AV-1 inhibits GAB 
and KGA are different.
Homologous  modeling,  docking  studies,  and 
binding site analysis
Based on the structure-activity relationships and 
inhibition modes analyzed above, we sought to determine 
the possible location of the AV-1-binding site on GAB 
[3]. Homologous modeling for GAB was conducted using 
the human GLS1 crystal structure 3UO9 and AutoDock 
Vina (http://vina.scripps.edu/). AutoDock Vina was further 
used to carry out a docking study for compound AV-1 
over the entire surface of the homologous modeled GAB 
dimer or monoer. The simulated pocket for AV-1 binding 
from docking showed major hydrogen bond and van der 
Waals interactions between AV-1 with the GAB residues 
H408, Q452, K453, S456, H461 and H472 (Figure 2A). 
The binding pocket is located at the C-terminal end of the 
GAB monomer, close to the dimer interaction interface. 
However, no inter-monomeric interactions were found 
for AV-1 and therefore it is assumed that one AV-1 binds 
to one GAB monomer as shown in Figure 2B. Further 
sequence  comparison  of  KGA  and  GAB  at  the AV-1 
binding  region  indicate  that  the  GAB  residues  Q452 
and K453 were differentiated from those corresponding 
residues of KGA H519 and D520 (Figure 2C).
Mutagenesis studies to validate the interactions for 
selectivity were next carried out. When the residues Q452 
and K453 in GAB were mutated into His or Asp to give the 
mutants Q452H, K453D or Q452H/K453D, the inhibitory 
effect significantly decreased: IC50 values of 0.28 ± 0.02 
µM (wild type), 1.33 ± 0.32 µM (Q452H), 4.17 ± 0.11 
µM (K453D), and 5.51 ± 0.28 µM (Q452H/K453D) were 
measured. These results demonstrate that the effects of 
the two GAB point mutations in decreasing AV-1 potency 
were additive. On the contrary, when the corresponding 
residues H519 and D520 in KGA were mutated into Gln 
or Lys to give the mutants H519Q, D520K or H519Q/
D520K, the inhibitory effect increased: IC50 values of 2.1 
± 0.1 µM (wild type), 1.67 ± 0.12µM (H519Q), 0.29 ± 
0.03 µM (D520K), and 0.23 ± 0.03 µM (H519Q/D520K) 
were measured. These results demonstrate that the effects 
of the two KGA point mutations reversely increased AV-1 
potency. 
Moreover, AV-1 comparably inhibited the wild type 
and the two KGA mutants corresponding to those of GAC 
(F318Y/F322S; Y394L)  (Figure  2D)  while  these  two 
KGA mutant enzymes were resistant to BPTES inhibition 
due to loss of key interactions demonstrated from co-
crystallization data previously reported (Figure 2D) [3]. 
Therefore, we conclude that the interactions between 
AV-1 and GAB residues Q452 and K453 determine the 
selectivity for GAB over KGA.
GLS2  inhibition  via  AV-1  compound  or  RNA 
silencing  exhibits  anti-cancer  cell  proliferation 
and  anti-  anchorage-independent  colony 
formation
GAB  and  KGA  protein  expression  levels  were 
found to be higher in human hepatoma HepG2 and lung 
carcinoma A549 cells than those in fibroblast cell lines 
Detroit 551 and WI-38, whilst GAC expression levels 
were not significantly changed (Figure 3A). LGA protein 
expression was low in each cell line but expressed 
slightly more in HepG2. KGA exhibited two major forms 
of protein, one of which was multi-phosphorylated as 
demonstrated by an addition of phosphatase experiment 
that affected the phosphorylation of KGA and changed 
the electrophoretic mobility of KGA protein in SDS gel 
(Figure 3A & Figure S1). The capacity of these compounds 
to inhibit growth of the cell lines A549, HepG2, MCF7 
(human  breast  carcinoma),  NCI-H460  (human  lung 
carcinoma), and SF268 (human glioblastoma) (Figure 3B, 
Table S1, and previously described [27, 28]) were found 
to be consistent with their glutaminase inhibition (Table 
1). Moreover, AV-1 inhibited colony formation of HepG2 
cells, as did GLS1 inhibitor BPTES, a reference control 
(Figure  3C,  left  panel). After  further  knocking  down 
GLS2 protein expression using a silencing RNA approach 
(see Materials and Methods), the A549 and HepG2 cell Oncotarget 6092 www.impactjournals.com/oncotarget
Figure 2: Docking studies and binding site analyses of AV-1 in GAB. (A) Docking simulation of AV-1 binding site in GAB. 
Magenta: H408 histidine; Yellow: Q452 glutamine; Orange: K453 lysine; Red: S456 serine; Cyan: H461 histidine; Blue: K472 lysine; 
Dashed lines: hydrogen bond interactions. AV-1 chemical structure was shown with interacted residues of GAB. (B) Overview of the 
proposed association of AV-1 in GAB tetramer. Left panel presents a top view and right panel a side view. AV-1 is presented in red and 
green stick figure for clarity, and the glutamate molecules are shown as orange spheres. (C) Primary sequence alignment of human KGA 
and human GAB around the simulated AV-1 binding site. Key interactive residues are denoted with arrows. Mutation sites for selectivity 
of GAB over KGA are denoted with red arrows. (D) IC50 values and selectivity index of AV-1 & BPTES for GAB or KGA wild-type and 
mutant enzymes. Mutations at residues Q452 and K453 of GAB into corresponding residues of KGA created GAB mutants GAB_Q452H, 
GAB_K453D, and GAB_Q452H/K453D. Mutations at residues H519 and D520 of KGA into corresponding residues of GAB created KGA 
mutants KGA_H519Q, KGA_D520K, and KGA_ H519Q/D520K. Mutations at residues F318/F322 and Y394 of KGA into corresponding 
residues of GAB or bacterial glutaminase created KGA mutants KGA_F318Y/F322S and KGA_Y394L [3]. Oncotarget 6093 www.impactjournals.com/oncotarget
Figure 3: GLS2 inhibition via AV-1 compound or RNA silencing exhibits anti-cancer cell proliferation and anti-
anchorage-independent colony formation. (A) GLS1 and GLS2 protein expressions in carcinoma cells HepG2 and A549 as well as 
normal fibroblast cell lines Detroit 551 and WI-38. (B) Dose dependent growth inhibition of active alkyl benzoquinones against carcinoma 
cells HepG2 and A549. (C) The effect of GLS2 inhibition via AV-1 or GLS2 knockdown on the colony formation of HepG2 cells. (D) 
Knockdown GLS2 expression significantly inhibited the carcinoma HepG2 and A549 cells growth. Shown are western blot analysis for 
GLS2 expression levels and growth curves of un-transfected (parental) cells, shRNA-control cell (shRNA-control) and GLS2 shRNA 
knockdown cells. **P<0.005. (E) AV-1 treatments decreased intracellular glutaminase activity. (F) AV-1 treatments decreased intracellular 
glutamate levels. The cells lysates treated with AV-1 or BPTES were subject to glutaminase activity assay and glutamates levels (see 
experimental procedures). * P < 0.05, ** P < 0.01, *** P < 0.001. See also Figure S1 and Table S1.Oncotarget 6094 www.impactjournals.com/oncotarget
growth  were  decreased  by  ~45-81%  (Figure  3D)  and 
colony formation inhibited accordingly (Figure 3C, right 
panel). AV-1 treatment significantly decreased intracellular 
glutaminase activity and product glutamate levels (Figure 
3E & 3F). Therefore, the alkyl benzoquinones inhibited 
carcinoma cell growth by inhibiting cellular glutaminase 
activity. 
AV-1 compound induces autophagy and activates 
AMPK
Anti-cancer agents usually induce diversified forms 
of cell death including apoptosis and autophagy [29]. 
To examine whether AV-1 inhibited cell growth leads to 
cell death, the cell death-related apoptosis and autophagy 
pathways were examined in AV-1 treated HepG2 cells. 
Autophagic  activity  was  monitored  by  tracking  the 
conversion  of  LC3-I  to  LC3-II. A  reliable  marker  of 
autophagosome LC3 is a mammalian homolog of yeast 
Atg8  [30].  It  was  found  that  LC3-II  production  was 
induced after the treatment of HepG2 cells with AV-1 for 
24-72 h (Figure 4A), but the apoptosis marker-cleaved 
caspase 3 [31] was not detected (Figure 4A). Because 
glutaminase inhibition in cancer cells decreases cellular 
energy production and results in nutrient depletion [5] 
(Figures  3  B-F);  and  because  autophagy  is  generally 
activated by conditions of nutrient deprivation [16], we 
concluded that induction of autophagy by AV-1 treatment 
was responsible for cell death (Figures 3B-E and 4A).
Autophagy is initiated and promoted by activation of 
AMPK_ULK1 axis signaling, but inhibited by mTORC1 
[16]. Therefore, we examined the effects of AV-1 treatment 
on these signaling pathways in HepG2 carcinoma cells. 
Our  investigation  of  the  autophagy-related  AMPK 
signaling pathway regulated by AV-1 showed: i) AMPK 
was  phosphorylated  for  activation  0.5-3  h  after AV-1 
treatment (Fig 4B); ii) the moderate phosphorylation of 
ULK1 at Ser317 by AMPK [16] occurred at 3-12 h while 
the phosphorylation of ULK1 at Ser757 by mTOR [16] 
was significantly decreased up to 72 h after AV-1 treatment 
(Fig 4C); iii) The protein and phosphorylation (at Ser15) 
levels  of  autophagic  Beclin1  were  not  significantly 
affected and the level of phosphorylated BCL2 decreased 
up to 72 h after AV-1 treatment (Figure 4C). These 
results indicate that the AMPK and ULK1 were activated 
while mTORC1 activity was suppressed in HepG2 cells 
treated with AV-1. Moreover, AV-1 induced autophagy 
is independent of Beclin1 and phosphorylated BCL2 
signaling.
AV-1 compound treatment results in mTORC1 
inhibition through activated AMPK and inhibited 
P13K/Akt
To investigate how mTORC1 activity is regulated 
by AV-1, phosphorylation of the mTORC1 components 
mTOR, Raptor, and Tuberin were separately examined 
(Fig. 5A). Firstly, phosphorylation at Ser2448 and auto-
phosphorylation  at  Ser2481  of  mTOR  for  activation 
via PI3K/AKT [32, 33] started to level off around 12 h, 
and then gradually increased until phosphorylation was 
complete at 72 h in AV-1 treated HepG2 cells. On the 
contrary, gradually decreasing levels of phosphorylation 
for  these  two  sites  occurred  in  the  DMSO  vehicle 
Figure  4:  AV-1  induced  cell  autophagy  through 
activated AMPK and ULK1. (A) Effects of AV-1 treatment 
on the induction of apoptosis and autophagy in HepG2 cells 
manifested by cleavage caspase 3 or LC3B. (B) The effects of 
AV-1 on AMPK activation. C. The effects of AV-1 on activation 
of  ULK1  and  BCL2  associated  Beclin1.  HepG2  cells  were 
treated  with  vehicle  (DMSO)  or  AV-1  for  various  times  as 
indicated prior to cell lysis for western blot analysis with the 
antibodies indicated. The results shown are representative of 
three independent experiments. Oncotarget 6095 www.impactjournals.com/oncotarget
treatment. 
Secondly, another nutrient sensing residue, Thr2446 
of mTOR, which undergoes phosphorylation by AMPK 
to give inactivated mTOR under conditions of nutrient 
deprivation [34], underwent significant phosphorylation 
in the first 24 h, only to become dephosphorylated around 
48-72 h in HepG2 cells treated with AV-1. On the contrary, 
HepG2 cells treated with DMSO vehicle did not show 
phosphorylation at Thr2446 of mTOR in the first 12 h, 
but a gradual increase in phosphorylation occurred from 
24 h up to 72 h (Figure 5A). These results suggest that 
mTOR activity was inhibited for the first 12 h after AV-1 
treatment, after which it became activated again. 
Thirdly,  residue  Thr1462  of  Tuberin  (an  AKT 
phosphorylation  site  to  activate  mTORC1)  [35]  was 
phosphorylated all over the 72 h-time course and even 
getting  highly  phosphorylated  at  48-72  h  period  in 
the HepG2 cells treated with DMSO. However, AV-1 
treatment disabled Tuberin phosphorylation at Thr1462 
over the same time period (Figure 5A). These results 
suggested that AV-1 treatment likely inhibited PI3K/AKT 
activity and the resultant Tuberin (dephosphorylated at 
Thr1462) did contribute to inhibition of the mTORC1 
activity. 
Fourthly, a dramatic increase in phosphorylation of 
Raptor at Ser792 (a site for AMPK direct phosphorylation) 
for  mTORC1  inactivation  upon  AV-1  treatment  was 
observed compared to DMSO vehicle controls (Figure 5A 
upper panel). 
Fifthly, mTORC1 inhibition was further manifested 
by the elimination of phosphorylation of p70S6K and 
4E-BP, further downstream targets of mTORC1 by AV-1 
treatment (Figure 5A lower panel). 
Lastly, compound C (an AMPK inhibitor) attenuated 
the AV-1 induced phosphorylation of Raptor at Ser792 and 
Tuberin at Ser1387 (Figure 5B). In response to nutrient 
deprivation, Ser1387 of Tuberin gets phosphorylated by 
AMPK which also leads to mTORC1 inactivation [36]. 
On  the  contrary,  compound  C  reversed  the  decreased 
phosphorylation of ULK1 Ser757 (Figure 5B and Figure 
S2). 
Thus, we conclude that AV-1 inhibited intracellular 
glutaminase activity and resulted in decreased glutamate 
level in HepG2 cells, leading to autophagy by AMPK 
activation.  AV-1  treatment  activated  AMPK  which 
moderately phosphorylated ULK1 at Ser317 for autophagy 
initiation, and strongly phosphorylated Raptor at Ser792 
and Tuberin at Ser1387 for mTORC1 inactivation for 
Figure 5: AV-1 inhibits mTORC1 through AMPK activation. (A) Effects of AV-1 on mTORC1 inactivation. (B) AMPK inhibition 
reverses the AV-1 associated mTORC1 inhibition. HepG2 cells were treated with vehicle (DMSO), AV-1, or Compound C (an inhibitor 
of AMPK) for various times as indicated prior to cell lysis for western analysis with the antibodies indicated. (C) A scheme illustrating 
that AV-1 inhibits glutaminase, activates autophagic pathway through AMPK activation and mTORC1 inhibition. The results shown are 
representative of three independent experiments. See also Figure S2.Oncotarget 6096 www.impactjournals.com/oncotarget
ultimate autophagy. Figure 5 C illustrated the effects of 
AV-1 in cell growth inhibition and induction of autophagy 
through AMPK mediated moderate ULK1 activation and 
profound mTORC1 inactivation.
DISCUSSION
Herein,  we  report  that  natural  product  alkyl 
benzoquinones are novel inhibitors of the emerging cancer 
drug target glutaminase, a discovery made by screening 
a small collection of natural products. The chemical 
structures of the AV and AK compounds include a fatty 
acid moiety, reflecting the fact that fatty acids and fatty 
acyl-coenzyme A derivatives can modulate glutaminase 
activity [9]. Thus, the possibility arises that potent 
endogenous modulators may exist and play significant 
roles in regulating glutaminase activity under various 
physiological conditions. 
GLS2 expression was reported to be significantly 
increased in 186 human colon carcinoma samples. GLS2 
depletion in HT1299 lung cancer cells by siRNA increased 
the apoptosis cell population and, in combination with 
the inducers of ROS-dependent apoptosis doxorubicin or 
n-butyrate, further augmented the percentage of apoptotic 
cells [12]. These findings suggest a potential role of GLS2 
in anti-cancer therapies. In our study, the relative inhibitory 
activities of the alkyl benzoquinones of glutaminase were 
generally consistent with their respective activities for 
anti-cancer cell growth (Table1, Table S1, and Figure 
3B). Moreover, the GLS2 depletion in HepG2 cells also 
diminished cell growth (Figure 3D). Furthermore, AV-1 
and GLS2 depletion significantly suppressed the colony 
formation of HepG2 (Figure 3C). Inhibition of glutaminase 
activity in cancer cells by alkyl benzoquinones results 
in a deficient nutrient supply (Figure 3E), which leads 
to i) an AMPK-mediated moderate ULK1 activation; ii) 
AMPK-mediated phosphorylations on Raptor Ser792 and 
Tuberin Thr1387 and a PI3K/AKT inhibition mediated 
dephosphorylation  on Tuberin Thr1462,  which  results 
in  significant  mTORC1  inhibition;  and  ultimately  iii) 
induction of autophagy (Figures 4 & 5). Therefore we 
conclude that GAB/GLS2 inhibition plays a significant 
role in the anti-cancer mechanisms for compound AV-1.
Glutaminase inhibitors are poorly explored, with 
few classes of potent allosteric inhibitors identified, e.g. 
BPTES  and  dibenzophenanthridine-968  compounds 
[2-6,  10].  Co-crystallization  data  showed  that  BPTES 
selectively inhibits GLS1 (KGA and GAC) via binding a 
differentiated gating loop close to the glutamine substrate 
binding site and exerting an allosteric effect to lock the 
tetramer into a nonproductive conformation. The GAC 
point  mutants  GAC  F318Y/F322S  and  GAC  Y394L 
were resistant to BPTES inhibition indicating that these 
interacting residues, Phe 322 and Tyr 394, are important 
for BPTES selectivity [3]. Molecular docking studies were 
conducted to locate potential dibenzophenanthridine-968 
binding sites and site-directed mutagenesis performed 
to validate the important interacting residues. For 
example, two key residues Arg 539 and Phe 532 were 
mutated to construct R539L and F532L GAC mutants; 
dibenzophenanthridine-968  was  found  to  be  a  greatly 
inferior inhibitor of GAC mutants than wild type. In 
order to understand more about the binding site of 
AV  compounds,  homologous  modeling,  docking  and 
mutagenesis studies were used to propose an AV-1 
binding site in GAB, and the roles of interacted residues 
in AV-1 selectivity for GAB over KGA. The analysis of 
structure-activity relationships reveals the importance of 
the two keto or hydroxyl group at positions 1 and 4 at 
the benzoquinone core and an acetate group at position 2’ 
for AV-1 potency in inhibiting KGA and GAB. Docking 
studies found these side groups of AV-1 to interact with 
conserved residues Ser456 and Lys472 at GAB through 
hydrogen bonds (Figure 2A). In addition, replacement of 
the GAB residues Q452 and K453 with the corresponding 
KGA residues His519 and Asp520 affected glutaminase 
selectivity of AV-1 for GAB (GLS2) over KGA (GLS1) 
(Figure 2A & 2D), presumably because these residues 
interact with AV-1 through van der Waal forces. We 
constructed two KGA mutants corresponding to those of 
GAC (F318Y/F322S; Y394L) and tested their activities. 
As expected, BPTES was not a potent inhibitor of these 
two KGA mutants, whilst AV-1 inhibited both wild type 
KGA and the mutants to a similar degree (Figure 2D). This 
divergent differentiation of the isoforms of GAB and KGA 
presents the possible selective allosteric binding sites for 
GLS1 over GLS2 or GLS2 over GLS1. Moreover, these 
results clearly demonstrate that the proximal binding 
site  of AV-1  was  different  from  those  of  BPTES  and 
dibenzophenanthridine-968.
The amino acid sequences of the glutaminase 
isoforms are highly homologous (81% identity) within 
their catalytic core regions (Figure S3, [37-39]). The rest 
of heterogeneous regions present potential differentiated 
allosteric pockets subjected to various modulations in 
enzymatic  activity  as  evidence  by  inhibitors  BPTES, 
dibenzophenanthridine-968, and AV-1. The accessibility 
of  these  allosteric  pockets  to  small  physiological 
molecules would allow for physiological modulations in 
the enzymatic activity. Thus, the possibility of identifying 
more  allosteric  pockets  for  modulating  glutaminase 
isozymes merits further investigation.
MATERIALS AND METHODS
Cell culture, reagents, and western blotting
The cancer cell lines including HepG2 and A549 
were obtained from American Type Culture Collection 
(Rockville,  MD).  The  cells  were  cultured  in  DMEM Oncotarget 6097 www.impactjournals.com/oncotarget
medium with 10% FBS (v/v) and penicillin (100 units/
ml)/ streptomycin (100 mg/ml). Cultures were maintained 
in a humidified incubator at 37°C in 5% CO2/95% air. 
Dulbecco’s  Modified  Eagle  Medium  (DMEM),  fetal 
bovine serum (FBS), penicillin, streptomycin, and 
all other tissue culture reagents were obtained from 
GIBCO/BRL  Life  Technologies  (Grand  Island,  NY). 
Antibodies to GAPDH, caspase 3, LC3B, p-ULK1(S317), 
p-ULK1(S757),  Beclin1,  p-BCL2(S70),  p70S6K, 
p-p70S6K(T389),  4E-BP1,  α-tubulin,  4E-BP,  p-4E-
BP(S65),  p-eIF4B(S422),  mTOR,  p-mTOR(S2481), 
p-mTOR(S2448),  p-Raptor(S792),  Tuberin, 
p-Tuberin(T1462),  p-Tuberin(T1387),  p-AMPK(T172) 
and p-AMPK(S108) were from Cell Signaling Technology; 
antibody to p-Beclin1(S15) was from Abbiotec; antibodies 
to KGA and Raptor were from Abcam; antibodies to BCL2 
were from Upstate Biotechnology; antibodies to α-tubulin 
were from Chemicon International; antibodies to ULK1, 
β-tublin  and  AMPK  were  from  GeneTex;  antibodies 
to GAB were from abnova and Gene Tex; antibodies 
to GAC were from ProteinTech Group; antibodies to 
p-mTOR(S2446)  and  AMPK  were  from  Millipore; 
anti-mouse and anti-rabbit IgGs were obtained from 
PerkinElmer. Alkyl benzoquinones were purified from 
A. virens and A. kusukuensis [27, 28]. Compound C was 
obtained from Sigma–Aldrich (St. Louis, MO). Western 
blotting was performed as described [40]. 
Preparation of BPTES
The synthesis of BPTES was modified from one 
previously published [41]. Step 1 Procedure: A mixture 
of thiosemicarbazide (1.82 g, 20 mmol), thiodipropionic 
acid (1.78 g, 10 mmol) and POCl3 (15 ml) was heated at 
90 °C for 3 h. After obtaining a clear solution, the reaction 
mixture was cooled and poured in to 100 g of ice. The solid 
was filtered and the filtrate was adjusted to pH 14 using 
5N NaOH. The resulting white solid was filtered, washed 
with water and dried to give bis(aminothioldiazole) (2.3 
g, 80%).
Step 2 Procedure: NaH (60%, 660 mg, 16.5 mmol) 
was added to a solution of bis-(aminothioldiazole) (1.586 
g, 5.5 mmol) in THF (200 mL) at 0°C. After being stirred 
for 5 min, phenylacetyl chloride (2.2 mL, 16.5 mmol) 
was added to the reaction mixture and the mixture was 
continuously stirred at room temperature for 16 h. Water 
was added to quench the reaction and the resulting mixture 
was extracted with ethyl acetate. The organic layers were 
washed with brine, dried over sodium sulfate, filtered, 
and concentrated in vacuo to furnish the crude BPTES. 
The solid was redissolved in DMSO and triturated with 
methanol to give BPTES as a white solid (518 mg, 18%) 
m.p 234-235 °C; 1H-NMR (300 MHz, (CD3)2SO): 2.92 
(4H, t, J=7.2 Hz), 3.24 (4H, t, J=7.2 Hz), 7.31 (10H, m), 
12.67 (2H, NH). Purity: 99.12% (RS-HPLC)
Cloning,  expression,  and  purification  of 
glutaminases (KGA and GAB)
The  cDNA  clone  MGC:33744  IMAGE:5263220 
(Invitrogen Inc., USA) was used to amplify a KGA cDNA 
fragment of 1644 bp (residues Leu123-Leu669) by PCR 
with primers 5’-ATACGCGGATCCCTGGTGGCC 
TCAGGTGAAAA-3’  and  5’–GTAAAGGAAAAAA 
GCGGCCGCTTACAACAATCCATCAAGAT-3’ 
containing BamHI and NotI, respectively, for subsequent 
sub-cloning.  The  cDNA  fragment  of  KGA  digested 
with BamHI and NotI at each end was ligated into the 
pET28a(+) vector (Novagen) and expressed as a his-tag 
fusion.  Escherichia coli  strain  BL21(DE3)pLysS  was 
transformed with the resulting plasmid, pET28a(+)-KGA, 
and then cultured in Luria-Bertani broth medium in the 
presence of kanamycin. Once the cultures reached an 
absorbance at 600 nm of 0.5 to 0.6, they were induced with 
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
overnight. The cells were harvested by centrifugation at 
10,000 rpm for 15 min at 4°C and resuspended in lysis 
buffer (5 mM Tris-HCl [pH 8.0], 50 mM NaH2PO4, 300 
mM NaCl and 10 mM imidazole) for sonication. The 
filtered supernatant was applied to an affinity column, 
HisTrapTM HP 1 x 5 mL (GE Healthcare), and washed 
with lysis buffer containing 10 mM β-mercaptoethanol 
(β–ME), 5% glycerol, 0.1% Triton X-100 and 100-150 
mM imidazole. His-tagged KGA was eluted with lysis 
buffer containing 10 mM β–ME, 5% glycerol, 0.1% Triton 
X-100 and 500 mM imidazole. The eluted protein was 
exchanged to 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 
10% glycerol, and 2 mM dithiothreitol by using a PD-10 
Desalting column (GE Healthcare). The concentration of 
the purified protein was determined by use of the Bio-Rad 
protein assay reagent with a standard curve plotted against 
bovine serum albumin. 
Equivalent construct of GAB (Pro56-Val602) was 
amplified from the cDNA clone MGC: 195512 IMAGE: 
100066375  (Invitrogen  Inc.,  USA).  The  sequences  of 
the primers were: 5’- GGAGGCGCGGATCCCCGC 
AGCACCAGGATCATG-3’  (BamHI)  and 
5’- GCAAGGAAAAAAGCGGCCGCAGCG 
CTATACCATGCTTTCTAAGTTCTC-3’  (Notl).  The 
resultant GAB-expression vector, pET28a(+)-GAB, was 
transformed into Escherichia coli strain C41(DE3)pLysS 
(Yeastern Biotech Co., Taiwan). The expression protocol 
was followed as that protocol of KGA construct. The cells 
after induction were collected and resuspended in lysis 
buffer (50 mM Tris-HCl pH 8.5, 500 mM NaCl, 10% 
glycerol, and 10 mM β–ME) for sonication. The filtered 
supernatant was applied to a Ni+-charged affinity column 
(GE Healthcare), and washed with lysis buffer containing 
50 mM imidazole. His-tagged GAB was eluted with lysis 
buffer containing 200 mM imidazole. The eluted GAB 
was exchanged to 20 mM Tris-HCl (pH 8.0), 300 mM 
NaCl, 50% glycerol, and 2 mM dithiothreitol by using a Oncotarget 6098 www.impactjournals.com/oncotarget
PD-10 Desalting column (GE Healthcare).
Glutaminase activity assays and kinetic studies
Human glutaminase activity was measured using 
a  two-step  assay  as  described  previously  [42,  43]. A 
microtiter assay format was used to facilitate the collection 
of multiple data points. Typically, 10 μl of compound, 
which was dissolved in DMSO, was added to 80 μl of 
an initial assay mix (0.1 mM hKGA, 0.2 mM EDTA and 
50 mM Tris/acetate, pH 8.6). Samples were incubated at 
25°C for 10 min and then 10 μl of 200 mM glutamine 
were added to the reaction mix. After adding glutamine, 
the reactions were incubated at 37°C for 60 min and 
then quenched by the addition of 10 μl of 0.6 M HCl. 
Subsequently, 100 μl of a second reaction mixture (3.7 
units of purified bovine liver glutamate dehydrogenase, 
160 mM Tris/acetate [pH 9.4], 400 mM hydrazine, 5 
mM ADP and 2 mM NAD+) was added to the stopped 
first reaction mixture and incubated for 30 min at 25°C. 
The absorbance at 340 nm was measured using a Wallac 
Victor2V plate reader (PerkinElmer), fitted with a 340 nm 
excitation filter. Sample absorbance was measured against 
a blank, containing no human glutaminase.
The kinetic constants Km and Vmax were determined 
by  using  Kaleida  Graph  software  (Synergy  Software) 
to  calculate  a  non-linear  least-squares  fit  for  all  the 
data points to the Michaelis–Menten equation. The Ki 
values for AV-1 were determined by using the Cheng-
Prusoff equation; Ki=IC50/(1 + [S]/Km) where [S] is the 
concentration of the glutamine.
In vitro  carcinoma  cell  growth  inhibition  and 
colony formation assays
A549 lung carcinoma and HepG2 hepatocarcinoma 
cells were seeded at 4000 and 10000 cells/well 
respectively in 96-well plates, as previously described for 
cell growth inhibition assay [27, 44]. To assess anchorage-
dependent colony formation effect, the cells (1000 cells/
well) were seeded in a six-well plate for 20-24 h prior to 
treatments of vehicle DMSO or compounds as indicated. 
Culture medium containing vehicle DMSO or compounds 
as indicated was changed twice a week. After a 21-day 
treatment, the cell colonies were rinsed with PBS, fixed in 
3:1 ratio of methanol and acetic acid, stained with 0.05% 
crystal violet.
Determination  of  intracellular  glutaminase 
activity and glutamate levels
Determination of intracellular glutaminase activity 
was modified from above described two-step glutaminase 
assay. Step one mixture of a 100 µl solution containing 
20µg cell lysate, 0.2 mM EDTA , 50 mM Tris/acetate (pH 
8.6), and 150 mM phosphate, was incubated at 37°C for 60 
min and the reaction was stopped by 10 µl of 0.6 M HCl. 
Subsequently, 30 µl of the stopped reaction was subjected 
to the second reaction as described above for glutaminase 
assay. Glutamate levels were measured by using the 
Amplex Red Glutamine Acid/Glutamate oxidase assay kit 
(Invitrogen) according to manufacturer’s instructions.
Mutagenesis and docking
Site-directed mutagenesis was performed on the 
pET28a(+)-GAB  or  pET28a(+)-KGA  plasmids  using 
PfuUltra II Fusion HS DNA polymerase (Agilent 
Technologies) to create the GAB and KGA mutants. The 
deep view program (Version 3.7) of the Swiss-MODEL 
server was used to generate the three dimensional structure 
of  homologous  modeled  GAB.  Using  the  integrated 
sequence alignment tools and structural superimposition 
algorithms, the target sequence was mapped on the 
modeling templates. The sequence alignment was 
compared with crystal structure of the GAC (PDB code: 
3UO9) and the resulting model of GAB was analyzed 
using the Swiss-PDB server. Threading and folding 
recognition of GAB model was developed by PHYRE2 
web  server.  Docking  studies  were  performed  with 
AutoDock  Vina.  Autodock  input  files  were  prepared 
with  MGLTools  1.5.6.  Molecules  were  drawn  in 
ChemBioOffice 2010, and energy minimized using the 
MM2 force field in Chemdraw 3D. Visualization was 
performed with PyMOL 1.3, and graphics were prepared 
in  that  software.  SWISS  MODEL:  http://swissmodel.
expasy.org/ and PHYRE2: http://www.sbg.bio.ic.ac.uk/
phyre2/html/page.cgi?id=index.
GLS2 gene silencing
The knock down of GLS2 was carried out using two 
distinct shRNA plasmids (clone ID: TRCN0000051323 
and  TRCN0000051327,  Academia  Sinica,  Taiwan) 
directed against the two isoforms of GLS2 enzyme (GAB 
and  LGA).  The  shRNA  plasmid  (TRCN0000231759, 
Academia Sinica, Taiwan) against of GFP was as a 
negative control. The shRNA plasmids were transfected 
in A549 cells, or HepG2 cells using FuGene 6TM (Roche). 
Stable cell clones were grown in the presence of 1 µg/mL 
puromycin. Established cell lines were further verified by 
anti-GAB western blot analysis to assess the cells growth.
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